Log in

NYSE:AGEAgeX Therapeutics Stock Price, Forecast & News

+0.02 (+2.30 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $0.89
50-Day Range
MA: $0.86
52-Week Range
Now: $0.89
Volume148,420 shs
Average Volume392,389 shs
Market Capitalization$33.48 million
P/E RatioN/A
Dividend YieldN/A
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$1.73 million
Book Value$0.07 per share


Net Income$-12,150,000.00
Net Margins-658.11%


Market Cap$33.48 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive AGE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGE and its competitors with MarketBeat's FREE daily newsletter.

AgeX Therapeutics (NYSE:AGE) Frequently Asked Questions

How has AgeX Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

AgeX Therapeutics' stock was trading at $0.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AGE stock has increased by 1.0% and is now trading at $0.8891. View which stocks have been most impacted by Coronavirus.

When is AgeX Therapeutics' next earnings date?

AgeX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for AgeX Therapeutics.

How were AgeX Therapeutics' earnings last quarter?

AgeX Therapeutics (NYSE:AGE) issued its earnings results on Thursday, May, 14th. The company reported ($0.08) EPS for the quarter. The company had revenue of $0.52 million for the quarter. AgeX Therapeutics had a negative return on equity of 334.65% and a negative net margin of 658.11%. View AgeX Therapeutics' earnings history.

Has AgeX Therapeutics been receiving favorable news coverage?

Media stories about AGE stock have trended negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AgeX Therapeutics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about AgeX Therapeutics.

Who are some of AgeX Therapeutics' key competitors?

What other stocks do shareholders of AgeX Therapeutics own?

Who are AgeX Therapeutics' key executives?

AgeX Therapeutics' management team includes the following people:
  • Mr. Alfred D. Kingsley, Exec. Chairman (Age 75)
  • Dr. Michael D. West, Pres, CEO & Director (Age 65)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
  • Mr. Nafees Naseer Malik, Chief Operating Officer
  • Dr. Aubrey D. N. J. de Grey BA, MA,Ph.D., Vice-Pres of New Technology Discovery

What is AgeX Therapeutics' stock symbol?

AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."

How do I buy shares of AgeX Therapeutics?

Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AgeX Therapeutics' stock price today?

One share of AGE stock can currently be purchased for approximately $0.89.

How big of a company is AgeX Therapeutics?

AgeX Therapeutics has a market capitalization of $33.48 million and generates $1.73 million in revenue each year.

What is AgeX Therapeutics' official website?

The official website for AgeX Therapeutics is www.agexinc.com.

How can I contact AgeX Therapeutics?

AgeX Therapeutics' mailing address is 965 ATLANTIC AVENUE SUITE 101, ALAMEDA CA, 94501. The company can be reached via phone at 510-671-8370.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.